Skip to main content
Medesis Pharma S.A. logo

Medesis Pharma S.A. — Investor Relations & Filings

Ticker · ALMDP ISIN · FR0010844464 LEI · 969500C15M96P00UR648 PA Manufacturing
Open in API
Filings indexed 118 across all filing types
Latest filing 2024-01-29 Earnings Release
Country FR France
Listing PA ALMDP

About Medesis Pharma S.A.

https://www.medesispharma.com/

Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.

Recent filings

Filing Released Lang Actions
MEDESIS PHARMA : Phase 2 clinical trial for the treatment of Alzheimer's disease - Completion of the 1st phase of double-blind treatment, with good patient retention and acceptance of the treatment
Earnings Release Classification · 95% confidence The document is explicitly titled 'PRESS RELEASE' and details several corporate updates: completion of a clinical trial phase, a scientific publication announcement, participation in an investor forum, and securing a new cash contribution (capital increase). This format, announcing key operational and financial highlights without being a full statutory report (like 10-K or IR), strongly suggests an Earnings Release (ER) or a general corporate announcement. Since it covers multiple non-financial operational milestones alongside a minor financing update, and it is structured as a press release, 'ER' (Earnings Release) is the most appropriate fit among the provided options for a company communicating key period updates, even if the period isn't explicitly Q4 or Q2. If it were purely about the financing, 'CAP' might apply, but the clinical trial update is primary. Given the structure and content announcing recent achievements and upcoming events, ER is the best classification. Q1 2024
2024-01-29 English
MEDESIS PHARMA : Étude clinique de phase 2 pour le traitement de la maladie d’Alzheimer - Finalisation de la 1ère phase de traitement en double aveugle avec une bonne rétention des patients et une bon
Capital/Financing Update Classification · 95% confidence The document is a press release from MEDESIS PHARMA dated January 29, 2024. It announces several key updates: the finalization of a phase of its Phase 2 clinical trial for Alzheimer's treatment, a scientific publication, participation in the BIOMED Forum, and securing a new cash injection (capital increase). The content focuses on operational and financial updates rather than being a formal regulatory filing like a 10-K, a detailed financial report (IR), or a proxy statement. Since it announces key business developments, including financing activities ('Nouvel apport en trésorerie') and clinical progress, it aligns best with an Earnings Release (ER) if it were periodic, but given the nature of announcing specific, non-periodic operational milestones and financing, it functions as a general corporate update. However, the most specific category for announcing financing/capital structure changes is 'Capital/Financing Update' (CAP). The document explicitly details securing an 'augmentation de capital d'environ 400 k€'. While it contains elements of clinical updates, the prominent announcement of securing new cash makes CAP a strong fit, though ER is also plausible for a biotech update. Given the explicit mention of securing capital, CAP is the most precise fit among the options for this specific announcement type, even though it's not a standard quarterly earnings release.
2024-01-29 French
MEDESIS PHARMA : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S2 2023
Regulatory Filings Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" and specifically reports on the "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S2 2023" (Semi-annual report of the liquidity contract for H2 2023). It details the status of shares and cash held under a liquidity contract as of June 30, 2023, and December 31, 2023, along with transaction volumes for the second half of 2023. This type of regular, periodic disclosure regarding market making or liquidity arrangements is a specific type of corporate announcement. It is not a full Annual Report (10-K), an Interim Report (IR), or a standard Earnings Release (ER). Since it is a formal press release detailing the status of a specific financial arrangement (liquidity contract), it fits best under the general category of Regulatory Filings (RNS) as it is a required disclosure, although it is highly specific. However, given the context of financial reporting, a liquidity contract report is often considered a specific regulatory filing or a general corporate update. Since there is no specific code for 'Liquidity Contract Report', RNS (Regulatory Filings / Miscellaneous) is the most appropriate fallback for a formal, periodic, non-core financial statement announcement. The document length is substantial (over 21k chars), so it is not an RPA.
2024-01-12 French
MEDESIS PHARMA CONFIRME SON ÉLIGIBILITÉ AU DISPOSITIF PEA-PME
Regulatory Filings Classification · 100% confidence The document is a press release dated January 12, 2024, announcing that MEDESIS PHARMA confirms its eligibility for the PEA-PME investment scheme for the year 2024. This announcement relates to the company's capital structure and investment eligibility criteria (employee count, revenue/balance sheet thresholds) as defined by French financial law (Code monétaire et financier). This topic falls under updates related to the company's financing or capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a formal regulatory filing like a 10-K or IR, nor is it a dividend notice or management change.
2024-01-12 French
MEDESIS PHARMA : Apport en trésorerie
Capital/Financing Update Classification · 98% confidence The document is titled 'COMMUNIQUÉ DE PRESSE' (Press Release) and announces a specific financial event: 'réalisation d'une augmentation de capital de 440 k€' (completion of a capital increase of €440k). It details the issuance of new shares, the subscription price, and the impact on cash flow ('prolonger son horizon de trésorerie'). This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). Although it is a press release, the core subject matter is financing, which is more specific than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA), as it is the primary announcement of the event itself, not just a notice that a report is available.
2023-12-20 French
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2023
Interim / Quarterly Report Classification · 95% confidence The document is titled 'MEDESIS PHARMA ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2023'. It provides a detailed summary of the company's activities, R&D progress, and financial results for the first half of 2023, including a table of financial statements (balance sheet/income statement data). While it mentions the availability of the full 'Rapport Financier Semestriel 2023' at the end, the document itself contains the substantive financial data and management analysis for the interim period, qualifying it as an Interim/Quarterly Report (IR) rather than just an announcement. H2 2023
2023-10-27 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.